Core Insights - 20/20 BioLabs is advancing its patented protein tumor marker (PTM) based, machine learning derived multi-cancer early detection (MCED) methodology, which shows promise for earlier stage cancer detection compared to circulating tumor DNA (ctDNA) based methods [1][4][5] Group 1: MCED Methodology and Findings - Recent studies indicate that protein biomarkers may effectively identify early-stage cancers, addressing the limitations of ctDNA tests, which often fail to detect cancer until it has progressed [3][4] - A large-scale ctDNA-based MCED study in the U.K. has highlighted the biological constraints of ctDNA as a first-line screening tool for early-stage cancers, emphasizing the need for alternative approaches [2][4] - 20/20 BioLabs' OneTest for Cancer has demonstrated detection rates for early-stage cancers as high as 50% for certain tumor types, such as pancreatic and ovarian cancers, in asymptomatic populations [6] Group 2: Validation and Support for Protein Biomarkers - A multicenter validation study published in Nature's Precision Oncology showed consistent cancer signal detection across diverse populations, with measurable sensitivity even in Stage I disease [6] - A blinded validation study at MD Anderson Cancer Center reported that a protein-based multicancer test identified nearly 90% of early-stage lung cancers, indicating the effectiveness of protein tumor markers during early oncogenesis [6] Group 3: Strategic Approach and Future Directions - The company proposes a tiered approach to cancer screening, where protein-based tests like OneTest serve as the initial screening step, followed by ctDNA testing for individuals identified at mild risk [7] - The recent legislation passed by Congress to create a pathway for Medicare coverage of MCEDs starting in 2028 is seen as a significant advancement for cancer screening access [8] - 20/20 BioLabs is committed to building the evidence base for protein-based technologies and working with policymakers to ensure effective screening tools are available [8]
20/20 BioLabs Highlights Advantages of its Patented Protein Biomarker Technology for Multi-Cancer Early Detection in Light of Recent Studies